POINT Biopharma Global Inc., (PNT): Price and Financial Metrics
GET POWR RATINGS... FREE!
PNT Stock Price Chart Interactive Chart >
PNT Price/Volume Stats
|Current price||$8.12||52-week high||$11.72|
|Prev. close||$7.91||52-week low||$4.25|
|Day high||$8.30||Avg. volume||308,876|
|50-day MA||$7.68||Dividend yield||N/A|
|200-day MA||$7.54||Market Cap||731.81M|
POINT Biopharma Global Inc., (PNT) Company Bio
POINT Biopharma Global Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of radioligand therapies for the treatment of cancer. Its products include PNT2001, a PSMA radioligand that is in preclinical studies for early stage prostate cancer treatment; PNT2002, which is in Phase 3 studies to evaluate superiority to the standard of care in mCRPC patients; PNT2003, a somatostatin-targeted radioligand therapy that is in Phase 3 trials for the treatment of patients with somatostatin receptor-positive neuroendocrine tumors; and PNT2004, a radioligand that targets fibroblast activation protein-a. The company is based in Indianapolis, Indiana.
Most Popular Stories View All
PNT Latest News Stream
|Loading, please wait...|
PNT Latest Social Stream
View Full PNT Social Stream
Latest PNT News From Around the Web
Below are the latest news stories about POINT Biopharma Global Inc that investors may wish to consider to help them evaluate PNT as an investment opportunity.
INDIANAPOLIS, Feb. 17, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced that the Company’s Chief Executive Officer, Dr. Joe McCann will participate in the following upcoming investor conferences. B. Riley Securities’ Radiation Oncology Investor DayFormat: Fireside chatDate: Tuesday, February 22, 2022Time: 11:30 am ET Cowen & Co.
Phase 1 therapeutic trial for PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha (FAP-alpha) inhibitor program, planned for summer 2022 Initiated IND-enabling studies for next-generation actinium-225 radiolabeled PSMA targeted program, PNT2001, to support an IND/CTA filing expected H1 2023 INDIANAPOLIS, Feb. 14, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global
Recording the biggest intraday gain since Dember, POINT Biopharma (PNT +12.4%) has neared a two-month high after the company shared its latest updates on production and late-stage clinical trials. The company said that its Indianapolis manufacturing facility was launched in October 2021, and an Investigational New Drug (IND) amendment to...
Company’s radiopharmaceutical manufacturing facility now operational, supplying doses for the Phase 3 SPLASH trial – view the facility at manufacturing.pointbiopharma.com Will receive actinium-225 in 2022 from the US Department of Energy Isotope Program to support early-stage pipeline Dosimetry data from the lead-in cohort of the SPLASH trial in mCRPC will be published February 25th in an abstract for the 2022 SNMMI Mid-Winter & ACNM Annual Meeting Randomization phase of the SPLASH trial initiat
Toronto, A6, based Investment company Baskin Financial Services Inc. (Current Portfolio) buys CoStar Group Inc, Watsco Inc, Tricon Residential Inc, POINT Biopharma Global Inc, Broadcom Inc, sells Activision Blizzard Inc, Algonquin Power & Utilities Corp, Vanguard Short-Term Corporate Bond ETF, NVIDIA Corp, Bitfarms during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Baskin Financial Services Inc..
PNT Price Returns